UNSPSC 51384633: Phenylbutazone sodium

This classification denotes a therapeutic glucocorticoid and antiemetic agent with the molecular formula C19H19N2O2.NA, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 189M850I32. European Medicines Agency schedules phenylbutazone sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03773MIG. The term phenylbutazone sodium is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule phenylbutazone sodium under HS 29331910 and SITC 51571.

As of Q4 2014, PHENYLBUTAZONE SODIUM remains US FDA's Preferred Term for this commodity. SMILES: CCCC[C-]1C(=O)N(N(C1=O)C2CCCCC2)C3CCCCC3.[NA+].

UNSPSC 51384633 Phenylbutazone sodium is a Commodity code that nominally refers to a single veterinary anti-inflammatory product, but recent state and local solicitations tagged under this code do not reflect phenylbutazone procurement — instead, they cover emergency medical countermeasures (naloxone and drug deactivation systems), therapeutic pharmacy initiatives, and multi-source generic pharmaceuticals and over-the-counter products. The mismatch between the code's nominal scope and actual buying activity suggests that either the code has been broadly applied to cover a wider range of pharmaceutical procurement, or the opportunities have been miscoded. Based on the recent solicitations, state and local entities are actually procuring naloxone, safe drug deactivation systems, and generic pharmaceuticals through county health departments, state health and human services commissions, and cooperative purchasing alliances.

The geographic spread includes Florida (Seminole County), Texas (HHS Commission), and Minnesota (through MMCAP, which serves multiple states including Oregon). Representative recent opportunities include Seminole County, Florida's IFB60459723LAS for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, response due July 26, 2023; the Texas Health and Human Services Commission's RFI HHS0017013 for therapeutic pharmacy initiative direct-to-manufacturer prescription capabilities, response due April 3, 2026; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co.), with proposals due March 26, 2026 and contract effectiveness July 1, 2026. The cooperative purchasing vehicle and multi-state reach of MMCAP indicates that pharmaceutical procurement at scale often flows through established purchasing alliances rather than individual jurisdictions.